Suraksha Diagnostic Limited has launched a state-of-the-art genomics laboratory in Eastern India, expanding its diagnostic capabilities with a focus on genetic testing. The new facility, based in West Bengal, was inaugurated in the presence of Prof. Sukumar Mukherjee, a senior rheumatologist and mentor at Suraksha.
The initiative addresses the rising demand for genomic diagnostics in the region, especially as West Bengal continues to expand its medical infrastructure. The lab aims to support early risk detection and treatment planning, marking a shift toward preventive and personalized healthcare.
With an initial investment of ₹22 crore, Suraksha plans to invest an additional ₹46 crore over the next two years to further develop the lab into one of Asia’s most advanced genomics facilities. The lab is equipped with cytogenetics, microarray technology, Sanger sequencing, and multiple next-generation sequencers (NGS), covering a wide range of genetic testing.
The facility enables testing for chromosomal abnormalities including Down syndrome, Edwards syndrome, Patau syndrome, and various sex chromosome and microdeletion conditions. It also offers genetic counseling to support patient decision-making.
In oncology, Suraksha’s lab provides hereditary cancer testing for conditions like breast, ovarian, and colorectal cancers. The lab supports both germline and somatic mutation profiling, aiding in cancer risk assessment and targeted treatment approaches. With NGS-powered oncology panels, clinicians can identify mutations that inform therapy selection.
The testing process involves methods like karyotyping to assess chromosomal structures, chromosomal microarray for detecting small genetic changes, FISH for targeting specific gene issues, and sequencing technologies to provide in-depth genetic insights.
Suraksha’s genomics lab aims to support the growing need for precision diagnostics in West Bengal and across Eastern and North-Eastern India, contributing to the broader shift toward genetics-based healthcare in the country.
